Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026)
Viatris (VTRS) posted quarterly Other Non-Current Liabilities of $2.1 billion for Q1 2026, up 12.91% year-over-year from $1.8 billion in Q1 2025, and up 3.36% quarter-over-quarter from $2.0 billion in Q4 2025.
Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 12.91% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 12.91% YoY), while the FY2025 annual figure was $2.0 billion, up 3.9% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $2.1 billion, up from $2.0 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.1 billion in Q1 2026, with the low at $345.0 million in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $1.8 billion (2022), against an average of $1.6 billion.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities sank 79.94% in 2024, then surged 434.61% in 2025.
- Viatris' Other Non-Current Liabilities stood at $1.8 billion in 2022, then dropped by 13.64% to $1.5 billion in 2023, then climbed by 27.84% to $1.9 billion in 2024, then grew by 3.9% to $2.0 billion in 2025, then grew by 3.36% to $2.1 billion in 2026.
- Business Quant data shows VTRS's Other Non-Current Liabilities at $2.1 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Bn |
| Mar 31, 2026 | 2.08 Bn |
| Dec 31, 2025 | 2.01 Bn |
| Sep 30, 2025 | 1.82 Bn |
| Jun 30, 2025 | 1.84 Bn |
| Mar 31, 2025 | 1.84 Bn |
| Dec 31, 2024 | 1.94 Bn |
| Sep 30, 2024 | 1.87 Bn |
| Jun 30, 2024 | 345.00 Mn |
| Mar 31, 2024 | 345.00 Mn |
| Dec 31, 2023 | 1.52 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.67 Bn |
| Mar 31, 2023 | 1.72 Bn |
| Dec 31, 2022 | 1.76 Bn |
| Sep 30, 2022 | 1.75 Bn |
| Jun 30, 2022 | 1.81 Bn |
| Mar 31, 2022 | 1.88 Bn |
| Dec 31, 2021 | 1.93 Bn |
| Sep 30, 2021 | 2.05 Bn |